Most Read Articles
Rachel Soon, 22 Mar 2019

At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.

18 Mar 2019
Aspirin use is associated with a lower risk of glioma, according to data from the Glioma International Case-Control Study.
11 Apr 2019
Overall, 5-fluorouracil is more effective than imiquimod in reducing the risk of keratinocyte carcinoma, but there are no differences in the short- or long-term risk of subsequent site-specific keratinocyte carcinoma in a real-world practice setting, according to a new study.
18 Feb 2019
Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.

Carfilzomib-panobinostat combo safe, effective for relapsed/refractory multiple myeloma

04 Feb 2019

The combination of carfilzomib, a second generation proteasome inhibitor, and panobinostat, a histone deacetylase inhibitor, is a safe and effective steroid-sparing regimen for heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), a recent study has found.

Thirty-two RRMM patients (median age 66 years; 53 percent female) participated in the present study, most of whom (84 percent; n=27) were relapsed and refractory to their last line of treatment. The median number of previous lines of treatment was four.

The maximum tolerated doses (MTD) of carfilzomib and panobinostat were 36 mg/m2 and 20 mg, respectively. At these levels, the most common dose-limiting toxicities were grade 4 thrombocytopoenia and a grade 3 increase in creatinine levels.

Other treatment-related adverse events (AE) were also reported. Eleven (37 percent) patients developed at least one serious AE, while any-grade haematological AEs occurred in almost all (97 percent) of the participants. Treatment-emergent, nonhaematological AEs of any grade were similarly highly common (93 percent).

One patient developed a grade 3–4 cardiac AE, while another experienced cardiac arrest, a grade 5 AE. Six patients discontinued the study due to AEs such as thrombocytopoenia, bowel perforation and acute pancreatitis.

In terms of efficacy, the objective response rate (ORR) in the overall study sample was 57 percent. A third of the participants achieved partial response, while 17 percent and 7 percent showed very good partial response (VGPR) and complete response, respectively. The resulting clinical benefit rate was 70 percent. At the MTD, the ORR was 63 percent, and 25 percent of the participants achieved VGPR or better.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 22 Mar 2019

At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.

18 Mar 2019
Aspirin use is associated with a lower risk of glioma, according to data from the Glioma International Case-Control Study.
11 Apr 2019
Overall, 5-fluorouracil is more effective than imiquimod in reducing the risk of keratinocyte carcinoma, but there are no differences in the short- or long-term risk of subsequent site-specific keratinocyte carcinoma in a real-world practice setting, according to a new study.
18 Feb 2019
Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.